EMA Recommends Extension of Indications for Durvalumab to Include Treatment of Patients with Resectable NSCLC at High Risk of Recurrence By Ogkologos - March 28, 2025 720 0 Facebook Twitter Google+ Pinterest WhatsApp New indication concerns neoadjuvant and adjuvant treatment of patients with resectable non-small cell lung cancer Source RELATED ARTICLESMORE FROM AUTHOR In Memory of Hernán Cortés-Funes: Former ESMO President and Pioneer in Medical Oncology Immune Pathways Help Identify Patients with Cancer and HIV Most Likely to Experience Reservoir Decay with Anti-PD1 Therapy Shaping Future Oncology Leaders: ESMO Broadens Its Career Development Opportunities MOST POPULAR Tyrosine Kinase Inhibitor Prolongs Progression-Free Survival in Rare Neuroendocrine Tumours [ESMO... September 20, 2021 Nivolumab Appears to Boost Cure Rate in Advanced Hodgkin Lymphoma November 14, 2024 One Dose of Either a Bivalent or Nonavalent HPV Vaccine Provides... December 9, 2025 Is there a future without Pap testing? October 21, 2020 Load more HOT NEWS Invasive Lobular Carcinoma Is Invisible On Mammograms, Isn’t A Lump Adding Autologous Stem-Cell Transplantation to Triplet Treatment, Followed by Lenalidomide Maintenance... Efficacy of Selumetinib in Reducing Plexiform Neurofibroma Volume in Adults with... Coronavirus reports – Part 10: “I didn’t see my mum before...
